Research Analysts Set Expectations for TERN Q1 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Terns Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst E. Arce anticipates that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright has a “Neutral” rating and a $7.50 price target on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.28) per share.

A number of other equities research analysts also recently commented on TERN. JMP Securities lifted their target price on shares of Terns Pharmaceuticals from $15.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Tuesday, September 10th. BMO Capital Markets reiterated an “outperform” rating and issued a $26.00 price target (up previously from $19.00) on shares of Terns Pharmaceuticals in a research note on Monday, September 16th. Finally, Oppenheimer began coverage on shares of Terns Pharmaceuticals in a research note on Thursday, October 31st. They issued an “outperform” rating and a $82.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $27.25.

Terns Pharmaceuticals Trading Down 3.4 %

NASDAQ:TERN opened at $6.55 on Thursday. Terns Pharmaceuticals has a 12 month low of $3.51 and a 12 month high of $11.40. The company has a market cap of $460.73 million, a PE ratio of -5.75 and a beta of -0.32. The company has a 50 day simple moving average of $8.08 and a two-hundred day simple moving average of $7.46.

Insider Activity

In other news, CFO Mark J. Vignola sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $11.00, for a total transaction of $110,000.00. Following the transaction, the chief financial officer now directly owns 91,940 shares in the company, valued at approximately $1,011,340. This trade represents a 9.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jill M. Quigley sold 17,235 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $10.00, for a total transaction of $172,350.00. Following the transaction, the director now owns 15,000 shares in the company, valued at approximately $150,000. This represents a 53.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 15.10% of the company’s stock.

Institutional Investors Weigh In On Terns Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in Terns Pharmaceuticals during the third quarter valued at approximately $48,000. Simplicity Wealth LLC purchased a new position in shares of Terns Pharmaceuticals in the second quarter worth $72,000. Sio Capital Management LLC purchased a new position in shares of Terns Pharmaceuticals in the third quarter worth $83,000. Walleye Trading LLC purchased a new position in shares of Terns Pharmaceuticals in the first quarter worth $98,000. Finally, Kennedy Capital Management LLC purchased a new position in shares of Terns Pharmaceuticals in the first quarter worth $101,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.